Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733611 · ClinicalTrials.gov registry record · Phase 2
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
A Phase 2 study, sponsored by Replimune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05733611: Clinical Trial Phase 2 study, sponsored by Replimune.
NCT05733611 is a Phase 2 study that was terminated before completion, run by Replimune. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05733611, a Phase 2 study, was terminated before completion, sponsored by Replimune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
Primary Outcome
Percentage of subjects achieving objective response (complete response + partial response).
Interventions
- BIOLOGICAL RP2
- BIOLOGICAL atezolizumab
- BIOLOGICAL RP3
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2025-08-18 |
| Phase | Phase 2 |
Why NCT05733611 stopped before completion
NCT05733611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which RP2 is the first listed.
NCT05733611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05733611 about?
NCT05733611 is a clinical study titled "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC". This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
What is the current status of trial NCT05733611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-06-29. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT05733611?
The interventions under investigation include: RP2 (BIOLOGICAL), atezolizumab (BIOLOGICAL), RP3 (BIOLOGICAL), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05733611?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05733611's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI